Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Observer-Blind, Placebo-Controlled Proof-of-Concept Trial to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus Vaccine in Patients Who Have Undergone Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT05683457 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT05683457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05683457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Observer-Blind, Placebo-Controlled Proof-of-Concept Trial to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus Vaccine in Patients Who Have Undergone Allogeneic Hematopoietic Cell Transplantation (HCT)
Lead sponsor
ModernaTX, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 5, 2023
Completion date
March 6, 2027
Enrollment
84 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus infection